Selective sensitivity of Ewing's Sarcoma to the PARP inhibitor BMN 673

被引：0
|
作者：
Singh, Arun [1 ]
Chmielowski, Bartosz [1 ]
Jia, Weiping [1 ]
Clarke, Kareem [1 ]
O'Brien, Neil [1 ]
Dering, Judy [1 ]
Conklin, Dylan [1 ]
Shen, Yuqiao [2 ]
Post, Leonard [2 ]
Finn, Richard S. [1 ]
Slamon, Dennis J. [1 ]
机构：
[1] Univ Calif Los Angeles, Santa Monica, CA USA
[2] Biomarin, Novato, CA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3453
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
    Luis Ordonez, Jose
    Teresa Amaral, Ana
    Carcaboso, Angel M.
    Herrero-Martin, David
    del Carmen Garcia-Macias, Maria
    Sevillano, Vicky
    Alonso, Diego
    Pascual-Pasto, Guillem
    San-Segundo, Laura
    Vila-Ubach, Monica
    Rodrigues, Telmo
    Fraile, Susana
    Teodosio, Cristina
    Mayo-Iscar, Agustin
    Aracil, Miguel
    Maria Galmarini, Carlos
    Tirado, Oscar M.
    Mora, Jaume
    de Alava, Enrique
    [J]. ONCOTARGET, 2015, 6 (22) : 18875 - 18890
  • [2] Population Pharmacokinetics of BMN 673, a Novel PARP Inhibitor, in Beagle Dogs
    Qi, Yulan
    Musson, Don
    Tsuruda, Laurie
    Zhou, Huiyu
    Cheng, Alphonsus
    O'Neill, Charles
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S30 - S30
  • [3] PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
    Herriott, Ashleigh
    Tudhope, Susan J.
    Junge, Gesa
    Rodrigues, Natalie
    Patterson, Miranda J.
    Woodhouse, Laura
    Lunec, John
    Hunter, Jill E.
    Mulligan, Evan A.
    Cole, Michael
    Allinson, Lisa M.
    Wallis, Jonathan P.
    Marshall, Scott
    Wang, Evelyn
    Curtin, Nicola J.
    Willmore, Elaine
    [J]. ONCOTARGET, 2015, 6 (41) : 43978 - 43991
  • [4] BMN-673 Poly [ADP-ribose] Polymerase (PARP) Inhibitor Oncolytic
    Gras, Jordi
    [J]. DRUGS OF THE FUTURE, 2013, 38 (12) : 813 - 819
  • [5] Antitumor activity of the PARP inhibitor E7449 in Ewing's sarcoma
    McGonigle, Sharon
    Chen, Zhihong
    Miu, Jingzang Tao
    Huang, Kuan-Chun
    Kolber-Simonds, Donna
    Zhao, Nanding
    Twine, Natalie C.
    Cao, Qiongfang
    Kuznetsov, Galina
    Xu, Shanqin
    Nomoto, Kenichi
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [6] BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
    Soni, Aashish
    Lin, Xixi
    Mladenov, Emil
    Mladenova, Veronika
    Stuschke, Martin
    Iliakis, George
    [J]. CANCERS, 2022, 14 (22)
  • [7] Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors
    Henshaw, Joshua W.
    Zhou, Huiyu
    Herriott, Ashleigh
    Patterson, Miranda
    Wang, Evelyn W.
    Musson, Don
    de Bono, Johann
    Mina, Lida A.
    Ramanathan, Ramesh K.
    O'Neill, Charles
    Dorr, Andrew
    Curtin, Nicola J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [8] IN-VIVO METABOLISM AND DISPOSITION OF A NEW ANTICANCER PARP INHIBITOR BMN 673 IN RAT AND DOG
    Musson, Donald
    Musson, Donald G.
    Haroldsen, Peter
    Oppeneer, Todd
    Bashir, Mohammed
    O'Neill, Charles
    [J]. DRUG METABOLISM REVIEWS, 2012, 44 : 126 - 127
  • [9] Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
    Wilkerson, Paul M.
    Dedes, Konstantin J.
    Samartzis, Eleftherios Pierre
    Dedes, Ioannis
    Lambros, Maryou B.
    Natrajan, Rachael
    Gauthier, Arnaud
    Piscuoglio, Salvatore
    Topfer, Chantal
    Vukovic, Vesna
    Daley, Frances
    Weigelt, Britta
    Reis-Filho, Jorge S.
    [J]. ONCOTARGET, 2017, 8 (04) : 6057 - 6066
  • [10] Nanoformulations of the PARP inhibitors olaparib and BMN 673 for cancer nanotherapy
    Sridhar, S.
    Tangutoori, S.
    Baldwin, P.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 116 - 116
12345